180-76-7

Usage

Uses

Used in Pharmaceutical Synthesis:
1,4-Diazaspiro[5.5]undecane(8CI,9CI) is used as a key intermediate in the synthesis of various pharmaceuticals for its unique molecular structure that can be modified to create new medicinal compounds. Its ability to be incorporated into complex organic molecules makes it valuable in the development of novel drugs with specific therapeutic properties.
Used in Agrochemical Synthesis:
In the agrochemical industry, 1,4-Diazaspiro[5.5]undecane(8CI,9CI) is utilized as a building block in the creation of new agrochemicals. Its unique structure allows for the design of innovative compounds that can address specific agricultural needs, such as pest control and crop protection, by enhancing the effectiveness and selectivity of these chemicals.
Used in Organic Chemistry Research:
1,4-Diazaspiro[5.5]undecane(8CI,9CI) serves as an important subject in organic chemistry research due to its spiro carbon atom and bicyclic structure. Researchers use 1,4-Diazaspiro[5.5]undecane(8CI,9CI) to explore new synthetic pathways, reaction mechanisms, and to develop innovative methodologies in organic synthesis, contributing to the broader understanding of chemical reactions and the discovery of new synthetic strategies.
Overall, the versatility and unique structural features of 1,4-Diazaspiro[5.5]undecane(8CI,9CI) position it as a valuable compound across different sectors, including pharmaceuticals, agrochemicals, and academic research, where its potential applications are continuously being explored and expanded.

Upstream product

• 34899-90-6 1-bromocyclohexanecarbaldehyde 

Relevant academic research and scientific papers

Enhanced D1 Affinity in a Series of Piperazine Ring Substituted 1-Piperazino-3-Arylindans with Potential Atypical Antipsychotic Activity

A study of the effect of aromatic substitution on D1 and D2 affinity in a series of previously reported trans-1-piperazino-3-phenylindans shows similar structure-activity relationships for the two receptor sites. 6-Substituted derivatives have affinity for both receptors, and 6-chloro-or 6-fluoro-substituted derivatives show preference for D1 receptors.D1 affinity and selectivity are significantly increased in a series of new piperazine ring substituted derivatives.Potent D1 and D2 antagonism in vivo are confined to derivatives with relatively small substituents in the 2-position of the piperazine ring (e.g. 2-methyl, 2,2-dimethyl, 2-spirocyclobutyl or 2-spiro-cyclopentyl).Consequently, the effect of aromatic substitution is examined in a series of 1-(2,2-dimethylpiperazino)-3-arylindans.All these compounds except the 4-, 5-, 7- and 4'-chloro-substituted derivatives have potent D1 affinity (IC50's below 10 nM) and the majority of the compounds antagonize SKF 38393-induced circling in 6-OHDA-lesioned rats with ED50 values about 1μmol/kg.In vitro all compounds show preference for D1 receptors, but in vivo they are equally effective as D1 and D2 antagonists.The compounds have high affinity for 5-HT2 receptors and selected compounds show high affinity for α1 adrenoceptors.Furthermore, a subgroup consisting of (-)-38, (-)-39, (-)-41, and (-)-54 does not induce catalepsy in rats.These compounds have the potential of being "atypical" antipsychotics and have consequently been selected for further studies.The non-receptor-blocking enantiomers are shown to be inhibitors of DA and NE uptake in accordance with previous observations in compounds unsubstituted in the piperazinering.Two compounds, (+)-38 and (+)-40, block DA uptake with IC50 values below 10nM.Finally, the observed structure-activity relationships are discussed in relation to previously published pharmacophore models for D2 and 5-HT2 receptors.It is concluded that the piperazine substituents might induce a different binding mode at the dopamine receptor sites, perhaps only at the D1 receptor site.